Ceres Nanosciences, Inc.
Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.
Ceres Nanosciences, Inc.
Patents
Method for harvesting nanoparticles and sequestering biomarkers
2016-07-05 • US-9383299-B2
View DetailsMethod for harvesting nanoparticles and sequestering biomarkers
2013-02-26 • US-8382987-B2
View DetailsWhat We Do
Hydrogel particles functionalized for the capture and concentration of viruses and microbes from biological and environmental samples, improving detection in downstream analytical methods.
Hydrogel particles designed to capture and concentrate a broader range of microbes, including bacteria and viruses, from complex samples such as wastewater.
Kit using hydrogel particle technology to capture and concentrate low-abundance, low molecular weight proteins and peptides from biological fluids, enhancing proteome coverage for downstream analysis.
Particles designed to capture and concentrate extracellular vesicles from complex biological samples, providing an alternative to ultracentrifugation and size exclusion methods.
Kit for capturing and concentrating cell-free DNA from plasma samples, reducing genomic DNA contamination and improving yield and purity for downstream analysis.
Buffers designed to improve manual workflows for aqueous sample types and enable efficient lysis of microbes when used with Nanotrap Microbiome Particles.
Regenerative Medicine
Digital Health Technologies
Show More (1)Key People
News & Updates
Received Gates Foundation funding to support deployment of wastewater biosecurity products to global health testing sites in Africa and India.
Received funding to launch a new global product for biosecurity and disease surveillance.
Launched new Nanotrap® Extracellular Vesicle Particles for improved isolation from complex samples.
Awarded $8.2 million from the NIH RADx Initiative to support the development and implementation of wastewater-based surveillance systems for COVID-19, with an emphasis on underserved and vulnerable populations.
Completed a new 12,000-square-foot Advanced Particle Manufacturing Plant to expand Nanotrap® Particle manufacturing capacity for COVID-19 testing and future needs.
Assesses genome coverage across wastewater samples and demonstrates a scalable, high-throughput solution for near real-time influenza surveillance.